Introduction
============

Approximately 2%--3% of the world's population are chronically infected with hepatitis C virus (HCV),[@b1-ppa-12-2631] which can lead to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and subsequently death.[@b2-ppa-12-2631],[@b3-ppa-12-2631] Even in the absence of liver disease, chronic HCV can lead to worsening patient reported outcomes (PROs), such as health-related quality of life (HRQoL) and fatigue.[@b4-ppa-12-2631]--[@b6-ppa-12-2631] HCV treatment can potentially improve PROs; however, the effect of treatment on PROs may vary based on the tolerability profile of the treatment regimen used. For example, treatment regimens that contain interferon or ribavirin have been found to be associated with significantly lower HRQoL while patients are on treatment.[@b6-ppa-12-2631]--[@b8-ppa-12-2631] The health domains observed to be negatively affected include role limitations-physical, vitality, social functioning, and role limitations-emotional.[@b7-ppa-12-2631],[@b8-ppa-12-2631] In addition, interferon-based regimens have been associated with increased fatigue, which is a predictor of diminished PROs.[@b6-ppa-12-2631],[@b8-ppa-12-2631]--[@b10-ppa-12-2631]

The emergence of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic HCV. Patients treated with DAAs have been shown to achieve high sustained viro-logic response (SVR) rates and improved PROs as DAAs have substantially less disabling side effects compared to the conventional pegylated interferon and ribavirin treatment.[@b6-ppa-12-2631],[@b11-ppa-12-2631] Inclusion of PROs in clinical trials of HCV treatment has become increasingly important in recent years given that they provide a more complete assessment of the impact of treatment on the patient's experience.[@b6-ppa-12-2631],[@b11-ppa-12-2631],[@b12-ppa-12-2631] Further, improved PROs are linked to better treatment adherence, which is integral to the effectiveness of DAA treatment.[@b6-ppa-12-2631],[@b13-ppa-12-2631]--[@b16-ppa-12-2631] The potential variation in PROs between regimens can be assessed using data from randomized clinical trials; however, the often-reported change scores in PROs between regimens may be statistically significant, but not clinically meaningful. To ascertain if a change in PRO score is meaningful clinically, the minimal clinically important difference (MCID) is often used as the threshold value.[@b17-ppa-12-2631] MCID is originally defined as "the smallest difference which patients perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient's management".[@b18-ppa-12-2631]

In the C-EDGE Head-2-Head (H2H) open-label multinational trial, 255 patients were randomized to receive either elbasvir/grazoprevir (EBR/GZR) or sofosbuvir with pegylated interferon and ribavirin (SOF/PR) for the treatment of HCV.[@b19-ppa-12-2631] EBR/GZR was observed to have superior efficacy and safety in patients with HCV genotype 1 or 4 compared with SOF/PR. The aim of this study is to compare the impact of EBR/GZR vs SOF/PR on changes in PROs both during treatment and posttreatment and to assess whether any observed differences in PROs between the two treatment groups are clinically meaningful.

Patients and methods
====================

Study design
------------

This study analyzed the PRO data collected as part of the Phase III C-EDGE H2H study trial conducted in Europe and Turkey. In the trial, patients with HCV genotype 1, 4, and 6 who were either treatment-naïve or had prior treatment failures with pegylated interferon (PR) were randomized 1:1 to receive either EBR (50 mg)/GZR (100 mg) once daily for 12 weeks or SOF 400 mg once daily, pegylated interferon 1.5 µg/ kg once weekly, and weight-based ribavirin for 12 weeks. Details of the study design and results of the C-EDGE H2H trial have been previously reported ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT02358044).[@b19-ppa-12-2631] The protocol was approved by the independent ethics committee at each participating site, and all patients provided written informed consent. A list of investigators and independent ethics committee is included in [Table S1 of the online supplementary material](#SD1-ppa-12-2631){ref-type="supplementary-material"}.

PROs
----

PROs were collected as exploratory endpoints of the trial. This study analyzed the PRO data collected using the acute Short Form-36 version 2 (SF-36v2) and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale at the baseline visit, during treatment at week 4 (TW4) and 12 (TW12), and posttreatment follow-up week 12 (FW12). Both PRO instruments were self-administered by patients using an electronic data capture tool.

### SF-36v2^®^ Acute (1-week recall)

Form The SF-36v2 Form is a generic questionnaire comprising 36 items assessing one reported health transition item and eight health domains: Physical Functioning (10 items), Role Limitations-Physical (four items), Bodily Pain (two items), General Health (five items), Vitality (four items), Social Functioning (two items), Role Limitations-Emotional (three items), and Mental Health (five items).[@b20-ppa-12-2631] The SF-36v2 has good internal consistency and reliability with Cronbach's alpha coefficient ranging from 0.78 to 0.93 for all domains.[@b21-ppa-12-2631] The domain scores can be summarized into the physical component summary (PCS) and mental component summary (MCS) scores, which measure overall physical and mental well-being, respectively. The domain scale scores range from 0 to 100, with 100 representing the best health status. The two summary scores were linearly transformed using the population norms to the mean of 50 and a standard deviation (SD) of 10. The SF-36v2 has been used extensively in several studies with HCV populations.[@b8-ppa-12-2631],[@b11-ppa-12-2631],[@b22-ppa-12-2631]--[@b28-ppa-12-2631]

### FACIT-Fatigue Scale

The FACIT-Fatigue Scale version 4 comprises 13 items that assess tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily activities and functioning.[@b29-ppa-12-2631] The FACIT-Fatigue has a recall period of 7 days, and items are rated on a 5-point Likert-type response scale. A summary scale score is computed ranging between 0 and 52, where a higher score indicates less fatigue. This instrument has been demonstrated to be reliable and valid in patients with fatigue[@b29-ppa-12-2631] and has been used in HCV-infected populations.[@b11-ppa-12-2631],[@b25-ppa-12-2631],[@b27-ppa-12-2631],[@b30-ppa-12-2631]

Statistical analysis
--------------------

Patients who had at least one dose of study medication and had completed at least one baseline or post-baseline PRO assessment were included in the base analytical cohort. To evaluate the treatment effect on PRO scores, mean change from baseline in PRO scores was calculated at each assessment time point during treatment (TW4 and TW12) and posttreatment (FW12), with corresponding 95% CI. To examine the difference between treatment groups, between-group differences in mean change from baseline in PRO scores were similarly estimated at each PRO assessment time point during treatment (TW4 and TW12) and posttreatment (FW12), with corresponding 95% CI. Missing data were not imputed, and the estimation of mean scores was based on all available data at each time point.

Based on a previous study employing a modified Delphi technique, an expert panel reviewed existing published literature relating to HRQoL in HCV identified using a systematic review and came to the consensus that the Vitality domain of the SF-36 is the most relevant to HCV patients and that a difference of 4.2 points can be used to estimate the MCID in this population.[@b22-ppa-12-2631] However, no MCIDs are available for the remaining domains or component scores of the SF-36v2 or the FACIT-Fatigue for this specific patient population. Therefore, this study computed effect sizes by taking the between-group mean differences in PRO scores from baseline at each assessment time point, divided by the SD of the difference in scores. The effect sizes were then compared to the standardized criteria by Cohen, where 0.2, 0.5, and 0.8 indicate a small, moderate, and large effect, respectively.[@b31-ppa-12-2631]

Results
=======

A total of 255 out of the 257 randomized patients were included in the analysis. Two patients in the SOF/PR group did not receive any study medication and were excluded from the analytical cohort. There were 129 patients in the EBR/GZR group and 126 patients in the SOF/PR group. Baseline clinical and demographic characteristics are presented in [Table 1](#t1-ppa-12-2631){ref-type="table"}. The mean age of the patients was 48 years across both study groups. The majority of patients were White (99.2%), female (54.1%), and non-cirrhotic (83.1%). Over three quarters (77.6%) of patients had genotype *IL28B* non-CC, 82.0% had HCV genotype (GT)1b infection, and 74.9% were treatment naïve. These characteristics were comparable across both treatment groups. No GT6-infected patients were enrolled in this study. Baseline PRO scores are reported in [Table 2](#t2-ppa-12-2631){ref-type="table"} and were similar between treatment groups. Across all PRO assessment time points, none of the patients were missing all SF-36v2 or FACIT-Fatigue assessments. The overall completion rates for the SF-36v2 and FACIT-Fatigue were high, with \>92% and \>90% of the patients completing the SF-36v2 and FACIT-Fatigue, respectively, at all assessment time points.

Change in SF-36v2^®^ scores from baseline
-----------------------------------------

### During the treatment period

A decrease in SF-36v2 scores was observed from baseline to week 4 of treatment in both treatment groups ([Figure 1](#f1-ppa-12-2631){ref-type="fig"}), with the SOF/PR treatment group showing a greater decrement in scores. Although this trend of reduction in SF-36v2 scores persisted to week 12 of treatment in the SOF/PR treatment group, improvements in the General Health and Mental Health domains, as well as MCS scores, were observed in the EBR/GZR treatment group at week 12 ([Figure 1](#f1-ppa-12-2631){ref-type="fig"}). Compared to the SOF/PR treatment group, at TW12, patients in the EBR/GZR treatment group reported a more positive change in SF-36v2 scores across most domains of the SF-36v2 ([Figure 1](#f1-ppa-12-2631){ref-type="fig"}). Between-group differences in mean change from baseline in PRO scores were at least 4.80 across all domains, with the greatest difference detected for the Role Limitations-Physical (16.55 in TW4; 21.62 in TW12) and Vitality domains (16.81 in TW4; 20.48 in TW12) ([Figure 2](#f2-ppa-12-2631){ref-type="fig"}). The estimated effect sizes for the between-group change in mean scores ranged from 0.25 to 0.58 at TW4 and 0.42 to 0.70 at TW12. Further, at treatment week 12, except for the Bodily Pain and General Health domains, the effect sizes of the between-group differences of all other domains and summary scores were shown to be at least moderate (\>0.50).

### During the posttreatment follow-up period

After completion of treatment at FW12, mean improvements from baseline scores in five of the eight health domains and both summary scores were observed with the EBR/GZR treatment group ([Figure 1](#f1-ppa-12-2631){ref-type="fig"}). The declines in SF-36v2 scores observed during the treatment period for the SOF/PR group returned to near baseline scores or above. Although the EBR/GZR group demonstrated more improvement in scores across all health domains and summary scores, there were no statistical differences noted between the treatment groups (95% CI did not exclude 0). There was an overall improvement in SF-36v2 scores from baseline for both treatment groups at FW12, the effect sizes of between-group mean change in scores were small (all \<0.20) ([Figure 2](#f2-ppa-12-2631){ref-type="fig"}).

Change in FACIT-Fatigue Scale scores from baseline
--------------------------------------------------

### During the treatment period

Treatment with EBR/GZR had no significant impact on FACIT-Fatigue Scale scores throughout the treatment period (95% CI did not exclude 0) ([Figure 3](#f3-ppa-12-2631){ref-type="fig"}). In contrast, treatment with SOF/PR resulted in increased fatigue during the treatment period as indicated by the mean reduction of FACIT-Fatigue Scale scores from baseline ([Figure 3](#f3-ppa-12-2631){ref-type="fig"}). Significant between- group differences were detected in the mean change of FACIT-Fatigue Scale scores from baseline, at treatment week 4, and at treatment week 12 (7.41 in TW4 and 7.56 in TW12; 95% CI excludes 0) ([Figure 4](#f4-ppa-12-2631){ref-type="fig"}). Further, the estimated effect sizes for these differences were moderate (both \>0.50).

### During the posttreatment follow-up period

Upon completion of treatment and at FW12, there was no observed impact of EBR/GZR treatment on the FACIT-Fatigue Scale scores. The increase in FACIT-Fatigue Scale scores observed during the treatment period for the SOF/ PR group resolved, and a slight improvement in FACIT-Fatigue Scale scores from baseline was detected at FW12 (mean change =1.89, 95% CI excludes 0). No between-group difference in mean change of FACIT-Fatigue Scale scores from baseline was observed, and the estimated effect size was negligible ([Figure 4](#f4-ppa-12-2631){ref-type="fig"}).

Discussion
==========

This study examined the impact of EBR/GZR vs SOF/PR on changes in PROs both during and after treatment and assessed whether any observed differences in PROs between the two treatment groups were clinically meaningful. The findings from this study demonstrate that treatment with EBR/GZR resulted in a more favorable PRO profile as compared to treatment with SOF/PR during the treatment period. Specifically, improvements in SF-36v2 scores during treatment as well as posttreatment follow-up period were observed among patients treated with EBR/GZR. In contrast, treatment with SOF/PR resulted in worsening SF-36v2 and FACIT-Fatigue Scale scores during the treatment period. Of note, the between-group differences of the Vitality domain score of the SF-36v2 exceeded the previously established MCID of 4.2 throughout the treatment period. By the end of the treatment at TW12, the between-group differences in mean change scores from baseline for the FACIT-Fatigue Scale, the SF-36v2 summary scales, and most domains of the SF-36v2 had effect sizes that were at least moderate.

The study findings are corroborated by other studies that have also found a negative impact on PROs associated with regimens containing PR during the treatment period, especially when compared to all-oral DAA regimens that do not include PR.[@b6-ppa-12-2631],[@b11-ppa-12-2631],[@b24-ppa-12-2631]--[@b26-ppa-12-2631] For example, Younossi et al[@b25-ppa-12-2631] found that patients treated with sofusbuvir/velpatasvir reported improvements in scores of most of the SF-36v2 domains (except Role Limitations-Emotional) and FACIT-Fatigue Scale scores, whereas patients treated with sofosbuvir/ ribavirin reported decrements in these scores during the treatment period. Similar to our study, the impairment in PRO scores observed with the ribavirin-containing treatment group resolved after the treatment was completed.[@b25-ppa-12-2631] This suggests that the deterioration in PROs during treatment with SOF/PR is likely due to treatment-emergent adverse events. In the C-EDGE H2H trial, patients receiving SOF/PR were more likely to report flu-like syndrome, rash/pruritus, and anemia-related adverse events compared to patients receiving EBR/GZR.[@b19-ppa-12-2631]

Although we did not detect any clinically meaningful differences between treatment groups by the 12-week post-treatment follow-up period, in the EBR/GZR treatment group there still were significantly improved SF-36v2 scores from baseline in the domains of Physical Functioning, Role Limitations-Physical, General Health, Vitality, Mental Health, and both the PCS and MCS scales. Improvements in SF-36v2 scores started at week 4 of treatment and persisted till posttreatment FW12. These improvements observed at FW12 were also much larger in magnitude as compared to improvements achieved during week 4 and 12 of treatment, which may suggest that the observed PRO improvement in EBR/GZR is likely to persist posttreatment.

Our study results add to the evidence base that patients treated with newer generation DAA regimens without the use of PR result in more favorable PROs during the treatment period, which is likely due to better tolerability when compared to other treatment regimens containing PR. This finding has important implications as nonadherence due to treatment-related side effects or impaired HRQoL can contribute to early treatment discontinuation and, in turn, reduced effectiveness.[@b13-ppa-12-2631],[@b32-ppa-12-2631] Bernstein et al observed that among patients with HCV, fatigue scores and the physical and mental summary scale scores of the SF-36v2 were significantly associated with early discontinuation of HCV treatment.[@b32-ppa-12-2631] Similarly, another study observed that for patients receiving PR-containing regimens, lower physical-related PRO scores, particularly fatigue, were a major driver of treatment nonadherence.[@b13-ppa-12-2631] Taken together, these highlight the importance of minimizing PRO impairment during the treatment period as treatment adherence is associated with higher SVR rates.[@b13-ppa-12-2631],[@b15-ppa-12-2631] In regions such as Eastern Europe and Central Asia where PR is still a standard of practice and access to DAAs varies across countries,[@b33-ppa-12-2631],[@b34-ppa-12-2631] this likely has clinical implications. Based on our study results, patients treated with the 12-week pegylated interferon-containing regimen (ie, SOF/PR), which was the shortest interferon-based regimen available at the time of the study, reported significantly lower PRO scores throughout the treatment period compared to their baseline. This suggests that even a short course of interferon-containing therapy may not be well tolerated. Therefore, to avoid issues of treatment nonadherence or discontinuation associated with impaired on-treatment PROs, it is important to raise awareness and improve treatment access to PR-free DAA regimens in this region.

The study findings should be interpreted in light of several limitations. First, this study analyzed the data collected as part of a clinical trial, which necessitates close monitoring of patients during and posttreatment intervention. Therefore, real-world observational studies are needed to confirm the study results in the clinical setting. In addition, given the open-label design of the C-EDGE H2H trial, it is unknown how much of an impact knowing the treatment assignment might have affected patients' perceptions of their health status. Due to the small number of nonresponders in this study, the impact of achieving SVR on PROs was not evaluated. This study computed effect sizes of the between-group change in PRO scores and compared them to the standardized interpretation of Cohen to evaluate if the detected differences were clinically meaningful. Although this is a common distribution-based approach of determining MCID, it is known that different approaches tend to yield different values, and the distribution approach is sample-specific where the values calculated depend on the variability of the scores within this study.[@b17-ppa-12-2631]

Conclusion
==========

This study demonstrated that HCV treatment with EBR/GZR resulted in a significantly better PRO profile during the treatment period as compared to SOF/PR. Although the improvements in PROs eventually returned to pretreatment levels at the end of therapy, the deterioration of PROs experienced during the treatment periods may negatively influence adherence and ultimately contribute to an unfavorable clinical outcome. Therefore, when deciding on the optimal therapy for HCV treatment, it is important to consider the impact that treatment is likely to have on PROs.
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![Mean change in SF-36v2 scores from baseline.\
**Note:** Error bars indicate 95% CIs.\
**Abbreviations:** BP, bodily pain; EBR/GZR, elbasvir/grazoprevir; GH, general health; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning; RE, role limitations-emotional; RP, role limitations-physical; SF, social functioning; SOF/PR, sofosbuvir with pegylated interferon and ribavirin; VT, vitality.](ppa-12-2631Fig1){#f1-ppa-12-2631}

![Summary of between-group differences and effect sizes for change in SF-36v2 scores from baseline.\
**Notes:** Error bars indicate 95% CIs.\
**Abbreviations:** BP, bodily pain; EBR/GZR, elbasvir/grazoprevir; GH, general health; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning; RE, role limitations-emotional; RP, role limitations-physical; SF, social functioning; VT, vitality.](ppa-12-2631Fig2){#f2-ppa-12-2631}

![Mean change in FACIT-Fatigue Scale scores from baseline.\
**Note:** Error bars indicate 95% CI.\
**Abbreviations:** EBR/GZR, elbasvir/grazoprevir; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; SOF/PR, sofosbuvir with pegylated interferon and ribavirin.](ppa-12-2631Fig3){#f3-ppa-12-2631}

![Summary of between-group differences and effect sizes for change in FACIT-Fatigue scale scores from baseline.\
**Notes:** Error bars indicate 95% CIs.\
**Abbreviations:** BP, bodily pain; EBR/GZR, elbasvir/grazoprevir; FACIT-Fatigue Scale, Functional Assessment of Chronic Illness Therapy-Fatigue Scale.](ppa-12-2631Fig4){#f4-ppa-12-2631}

###### 

Baseline clinical and demographic characteristics of study sample

  Characteristics            Total               EBR/GZR (N=129)   SOF/PR (N=126)                                   
  -------------------------- ------------------- ----------------- -------------------- ------ -------------------- ------
  Age (mean, SD)             47.9 (12.4)         47.6 (12.4)       48.2 (12.4)                                      
  Gender                                                                                                            
   Male                      117                 45.9              55                   42.6   62                   49.2
   Female                    138                 54.1              74                   57.4   64                   50.8
  Race                                                                                                              
   White                     253                 99.2              128                  99.2   125                  99.2
   Asian                     [@b2-ppa-12-2631]   0.8               [@b1-ppa-12-2631]    0.8    [@b1-ppa-12-2631]    0.8
  *IL28B* genotype                                                                                                  
   CC                        52                  20.4              26                   20.2   26                   20.6
   Non-CC                    198                 77.6              100                  77.5   98                   77.8
   Missing                   5                   2.0               [@b3-ppa-12-2631]    2.3    [@b2-ppa-12-2631]    1.6
  Baseline HCV RNA                                                                                                  
   \>800,000 IU/mL           171                 67.1              90                   69.8   81                   64.3
   \>2,000,000 IU/mL         106                 41.6              57                   44.2   49                   38.9
   \>10,000,000 IU/mL        10                  3.9               4                    3.1    6                    4.8
   Baseline BMI (mean, SD)   25.8 (4.0)          25.9 (3.9)        25.6 (4.0)                                       
  HCV genotype                                                                                                      
   1a                        35                  13.7              [@b18-ppa-12-2631]   14.0   [@b17-ppa-12-2631]   13.5
   1b                        209                 82.0              105                  81.4   104                  82.5
   4                         11                  4.3               6                    4.7    5                    4.0
  Cirrhosis                                                                                                         
   Non-cirrhotic             212                 83.1              107                  82.9   105                  83.3
   Cirrhotic                 43                  16.9              [@b22-ppa-12-2631]   17.1   [@b21-ppa-12-2631]   16.7
  Prior treatment response                                                                                          
   Naïve                     191                 74.9              100                  77.5   91                   72.2
   PR null responder         25                  9.8               11                   8.5    14                   11.1
   PR partial responder      14                  5.5               6                    4.7    8                    6.3
   PR relapser               25                  9.8               12                   9.3    13                   10.3

**Abbreviations:** BMI, body mass index; EBR/GZR, elbasvir/grazoprevir; HCV, hepatitis C virus; PR, pegylated interferon and ribavirin; RNA, ribonucleic acid; SOF/ PR, sofosbuvir with pegylated interferon and ribavirin.

###### 

Baseline PRO scores of the treatment groups

  PRO instrument                EBR/GZR   SOF/PR                         
  ----------------------------- --------- -------- ------- ----- ------- -------
  SF-36v2                                                                
   Physical functioning         125       89.76    15.54   123   88.33   17.81
   Role limitations-physical    125       82.10    19.01   123   82.16   21.71
   Bodily pain                  125       87.56    18.58   123   85.21   21.07
   General health               125       68.98    18.57   123   65.98   18.29
   Vitality                     125       69.20    18.70   123   68.45   19.04
   Social functioning           125       88.60    17.32   123   87.09   18.24
   Role limitations-emotional   125       88.00    17.47   123   86.86   20.66
   Mental health                125       76.04    15.82   123   76.10   17.50
   PCS                          125       54.10    6.21    123   53.34   7.39
   MCS                          125       50.85    8.15    123   50.64   8.47
   FACIT-fatigue scale score    123       44.58    7.51    122   43.01   8.61

**Abbreviations:** EBR/GZR, elbasvir/grazoprevir; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; MCS, mental component summary; PCS, physical component summary; PRO, patient-reported outcome; SF-36v2, Short Form-36 version 2; SOF/PR, sofosbuvir with pegylated interferon and ribavirin.
